数位生物标记：开启疾病管理和药物研发的新视角

本报告深入探讨了製药业，并全面分析了数位生物标记在药物研究、药物研发和疾病管理中不断演变的作用。基于对顶尖专家的深入访谈，报告探讨了穿戴式装置、生物感测器和人工智慧驱动分析技术的进步如何实现持续、客观、以患者为中心的数据，从而增强临床试验和真实世界证据的生成。

主要的问题

• 1. 数位生物标记如何开启药物研发与疾病管理的新视野？
• 2. 製药公司如何利用数位生物标记来促进临床研发？
• 3. 验证和鑑定数位生物标记在临床应用中的关键挑战是什么？
• 4. 有哪些成功应用数位生物标记推进药物研发专案的案例？
• 5. 数位生物标记如何支持疾病管理和病患照护？
• 6. 数位生物标记在製药业的应用和采用的最新趋势是什么？
• 7. 生物製药公司未来有哪些机会可以利用数位生物标记来改善治疗结果？
• 8. 数位生物标记如何支持创新药物的报销？
• 9. 确保数位生物标记符合用途的关键考虑因素是什么？
• 10. 製药公司如何合作和投资以推进其数位生物标记策略？

主要企业

This report delivers a comprehensive analysis of the evolving role of digital biomarkers in pharmaceutical research, drug development and disease management. Based on in-depth interviews with leading experts, it explores how advances in wearable devices, biosensors and AI-driven analytics are enabling continuous, objective and patient-centric data to enhance clinical trials and real-world evidence generation.

The report explores the integration of digital endpoints into clinical development, the regulatory frameworks and validation challenges shaping their use, and the impact of digital biomarkers on patient monitoring, compliance and personalised medicine. It also considers collaborative strategies, emerging therapeutic use cases and the future trends influencing adoption across the biopharma landscape. Gain actionable insights into the opportunities and challenges of implementing digital biomarker strategies to support more efficient, data-driven and value-based healthcare.

Key Questions Answered:

• 1. How are digital biomarkers unlocking new insights in drug development and disease management?
• 2. In what ways are pharmaceutical companies using digital biomarkers to enhance clinical development?
• 3. What are the main challenges in validating and qualifying digital biomarkers for clinical use?
• 4. Where have digital biomarkers been successfully deployed to drive drug development programs?
• 5. How are digital biomarkers supporting disease management and patient care?
• 6. What are the latest trends in the adoption and application of digital biomarkers in pharma?
• 7. What future opportunities exist for biopharma to leverage digital biomarkers for improved outcomes?
• 8. How can digital biomarkers support the reimbursement of innovative medicines?
• 9. What are the key considerations for ensuring digital biomarkers are fit-for-purpose?
• 10. How are pharma companies collaborating and investing to advance digital biomarker strategies?

Key Companies:

Partial List of Participating Experts:

• Vice President, Clinical Outcome Assessment Program, Critical Path Institute, US
• Vice President, Critical Path Institute, US
• Executive Scientific Director, Research & Strategy, Modus Outcomes, US
• Science Director, VivoSense, Switzerland
• Vice President of Data Science, Mitra bio, UK
• Scientific Director, Tecniplast, Germany

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.